Last reviewed · How we verify
IPV SSI
IPV SSI is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes.
IPV SSI is an inactivated poliovirus vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes. Used for Poliomyelitis prevention in infants, children, and adults.
At a glance
| Generic name | IPV SSI |
|---|---|
| Also known as | IPV Vaccine SSI |
| Sponsor | Statens Serum Institut |
| Drug class | Inactivated viral vaccine |
| Target | Poliovirus serotypes 1, 2, and 3 |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains chemically inactivated (killed) poliovirus particles from serotypes 1, 2, and 3. When administered, it triggers both humoral (antibody) and cellular immune responses without causing disease, providing protection against poliomyelitis infection. This formulation is produced by Statens Serum Institut and represents a standard immunization approach for polio prevention.
Approved indications
- Poliomyelitis prevention in infants, children, and adults
Common side effects
- Injection site pain or swelling
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Single Session Intervention to Promote Hope (NA)
- Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months (PHASE3)
- Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age (PHASE3)
- 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents (PHASE1, PHASE2)
- 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (PHASE2)
- Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months (PHASE3)
- Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age (PHASE2)
- Influence of BCG on TDaP-IPV Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPV SSI CI brief — competitive landscape report
- IPV SSI updates RSS · CI watch RSS
- Statens Serum Institut portfolio CI